Barclays upgraded shares of bluebird bio (NASDAQ:BLUE – Get Rating) from an underweight rating to an equal weight rating in a research report released on Friday, Marketbeat reports. Barclays currently has $5.00 price target on the biotechnology company’s stock, up from their previous price target of $3.00.
A number of other equities research analysts also recently weighed in on BLUE. Morgan Stanley lowered their price target on bluebird bio to $3.00 and set an underweight rating on the stock in a research report on Tuesday, May 17th. Raymond James upgraded bluebird bio from a market perform rating to an outperform rating and set a $8.00 price target on the stock in a research report on Tuesday. Finally, Wedbush decreased their price objective on bluebird bio from $10.00 to $8.00 and set a neutral rating on the stock in a report on Tuesday, May 10th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, bluebird bio presently has a consensus rating of Hold and a consensus price target of $11.86.
bluebird bio Price Performance
NASDAQ:BLUE opened at $5.59 on Friday. bluebird bio has a 52-week low of $2.87 and a 52-week high of $26.00. The stock has a fifty day moving average of $4.22 and a 200 day moving average of $4.79.
Hedge Funds Weigh In On bluebird bio
A number of institutional investors have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. raised its holdings in bluebird bio by 81.2% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 94,875 shares of the biotechnology company’s stock worth $393,000 after purchasing an additional 42,503 shares in the last quarter. Monaco Asset Management SAM bought a new position in bluebird bio in the second quarter worth $1,267,000. SG Americas Securities LLC raised its holdings in bluebird bio by 133.1% in the second quarter. SG Americas Securities LLC now owns 28,253 shares of the biotechnology company’s stock worth $117,000 after purchasing an additional 16,130 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in bluebird bio by 45.4% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 313,207 shares of the biotechnology company’s stock worth $1,297,000 after purchasing an additional 97,827 shares in the last quarter. Finally, Parametrica Management Ltd bought a new position in bluebird bio in the second quarter worth $374,000. Institutional investors own 96.38% of the company’s stock.
About bluebird bio
bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.
- Get a free copy of the StockNews.com research report on bluebird bio (BLUE)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.